Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 18/20 | 0.56 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.48 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.45 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12952757 | 0.88 | TYR (0.50) | ERN1AURKATPX2AKR1C2AKR1C1 | |
| SCHEMBL29627452 | 0.87 | ERN1 (0.61) | ERN1 | |
| SCHEMBL1211619 | 0.87 | ERN1 (0.61) | ERN1 | |
| SCHEMBL12952823 | 0.84 | ERN1 (0.54) | ERN1AURKATPX2 | |
| SCHEMBL2534012 | 0.83 | ERN1 (0.43) | ERN1AURKATPX2AKR1C2AKR1C1 | |
| SCHEMBL6642692 | 0.82 | ERN1 (0.60) | ERN1 | |
| SCHEMBL2655961 | 0.81 | KIF11 (0.44) | ERN1AURKATPX2AKR1C2AKR1C1 | |
| SCHEMBL2539401 | 0.80 | CA12 (0.41) | ERN1AURKATPX2AKR1C2AKR1C1 | |
| SCHEMBL13580965 | 0.79 | KIF11 (0.44) | ERN1AURKATPX2AKR1C2AKR1C1 | |
| SCHEMBL24086095 | 0.79 | ERN1 (0.74) | ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633245-B2 | PAI-1 inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-8633245-B2 | PAI-1 inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-8044236-B2 | Inhibitors against plasminogen activator inhibitor-1 (PAI-1); anticoagulants; 2-(aryl or aralkyloxy-)-5-(aryl)phenyl}acetic acid (or derivatives of propionic acid, propenoic acid, N-oxamic acid or 1H-tetrazol-5-yl); occlusion, stenosis; low molecular weight; gene expression inhibition | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2011-10-25 | — | — | US | disclosed |
| US-8044236-B2 | Inhibitors against plasminogen activator inhibitor-1 (PAI-1); anticoagulants; 2-(aryl or aralkyloxy-)-5-(aryl)phenyl}acetic acid (or derivatives of propionic acid, propenoic acid, N-oxamic acid or 1H-tetrazol-5-yl); occlusion, stenosis; low molecular weight; gene expression inhibition | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2011-10-25 | — | — | US | disclosed |
| US-8044236-B2 | Inhibitors against plasminogen activator inhibitor-1 (PAI-1); anticoagulants; 2-(aryl or aralkyloxy-)-5-(aryl)phenyl}acetic acid (or derivatives of propionic acid, propenoic acid, N-oxamic acid or 1H-tetrazol-5-yl); occlusion, stenosis; low molecular weight; gene expression inhibition | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2011-10-25 | — | — | US | disclosed |
| EP-2272817-A1 | PAI-1 INHIBITOR | Institute of Medicinal Molecular Design, Inc. (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20090312315-A1 | PAI-1 INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090312315-A1 | PAI-1 INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-12-17 | — | — | US | disclosed |
| WO-2009125606-A1 | PAI-1 INHIBITOR | 株式会社医薬分子設計研究所 (JP) | 2009-10-15 | — | — | WO | disclosed |
| EP-2080751-A1 | CARBOXYLIC ACID DERIVATIVE | Institute of Medicinal Molecular Design, Inc. (JP) | 2009-07-22 | — | — | EP | disclosed |
| EP-2080751-A1 | CARBOXYLIC ACID DERIVATIVE | Institute of Medicinal Molecular Design, Inc. (JP) | 2009-07-22 | — | — | EP | disclosed |
| US-20080275116-A1 | Carboxilic acid derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-11-06 | — | — | US | disclosed |
| US-20080275116-A1 | Carboxilic acid derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-11-06 | — | — | US | disclosed |
| US-20080275116-A1 | Carboxilic acid derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312315-A1 | PAI-1 INHIBITOR | SERPINC1, SERPINE1, SERPINH1 | ERN1 539/4885AURKA 3797/4885TPX2 1545/4885 |
| US-20080275116-A1 | Carboxilic acid derivatives | SERPINE1, CTRL, SERPINC1 | ERN1 918/4885AURKA 953/4885TPX2 3404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.